Answers are grounded in this paper and cite their sources.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that is frequently overexpressed in many cancers and can be associated with cancer progression, poor prognosis, and treatment resistance. CIP2A was initially characterised as an inhibitor of protein phosphatase 2A (PP2A), thereby inhibiting the dephosphorylation and degradation of the transcription factor c-Myc. However, more recent evidence suggests that CIP2A has broader functions in cell cycle progression, genomic stability, and DNA damage repair. CIP2A is regulated at multiple levels, including transcriptional, post-transcriptional and post-translational mechanisms, allowing integration with several oncogenic signalling pathways. Elevated CIP2A expression has been reported in numerous haematological and solid malignancies, where it is frequently associated with poor clinical outcomes. Growing evidence supports the use of CIP2A as a prognostic biomarker, and its central role in tumour biology has established the CIP2A-PP2A interaction as a promising therapeutic target. Although challenges remain, including incomplete structural characterisation and the absence of clinically approved CIP2A-targeted therapies, continued research in biomarker development and drug discovery highlights the potential of CIP2A in personalised cancer treatment to improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Burnett et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: